Clinical trial
Lantus Versus Levemir Treat-To-Target
NCT00405418 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00405418 |
|---|---|
| Title | Lantus Versus Levemir Treat-To-Target |
| Official title | Target Glycemic Control and the Incidence of Documented Symptomatic Hypoglycemia in Insulin naïve Subjects With Type 2 Diabetes Failing on Oral Hypoglycemic Agent(s) and Treated With Insulin Glargine or Insulin Detemir. |
| Acronym | L2T3 |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin glargine, Insulin Detemir |
| Enrollment | 973 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2008 |
| First posted | Nov 30, 2006 |
| Last update posted | Sep 15, 2009 |
| Countries | Australia, Brazil, Canada, Denmark, Finland, Germany, India, Ireland, Netherlands, Portugal, Romania, Russia and 8 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: